ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "SLE"

  • Abstract Number: 605 • 2013 ACR/ARHP Annual Meeting

    Childhood Lupus Nephritis: Long Term Outcome Of 91biopsy Proven Cases From India

    Puja Srivastava1, Bonnie Abujam2, Ramnath Misra1, Able Lawrence1, Vikas Agarwal1 and Amita Aggarwal1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Postgraduate Institute of Medical Education and Research, Chandigarh, India

    Background/Purpose: Childhood SLE has a higher prevalence of lupus nephritis (LN) as well as proliferative LN than adults. There is ethnic variation in response to…
  • Abstract Number: 2724 • 2013 ACR/ARHP Annual Meeting

    cAMP Responsive Element Modulator (CREM)α Governs CD8 Expression and Contributes to the Generation of CD3+CD4–CD8– T Cells in Lupus

    Christian M. Hedrich1, José C. Crispín1, Thomas Rauen1, Christina Ioannidis1, Tomohiro Koga2, Noe Rodriguez Rodriguez2, Sokratis A. Apostolidis3, Vasileios C. Kyttaris2 and George C. Tsokos1, 1Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, 2Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: CD3+CD4-CD8- "double negative" T cells are expanded in the peripheral blood of patients with systemic lupus erythematosus (SLE) and lupus-prone mice. Double negative T…
  • Abstract Number: 1637 • 2013 ACR/ARHP Annual Meeting

    IKZF1 Modulates PP2Ac Expression Through An Intronic Binding Site

    Kamalpreet Nagpal1, Katsue S. Watanabe2 and George C. Tsokos3, 1Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

    IKZF1 modulates PP2Ac expression through an intronic binding siteKamalpreet Nagpal1, Katsue Sunahori2, George C. Tsokos11Department of Medicine, Division of Rheumatology, Beth Israel Deaconess Medical Center,…
  • Abstract Number: 1062 • 2013 ACR/ARHP Annual Meeting

    The Brief Index Of Lupus Damage As a Predictor Of Mortality In a Cohort Of Patients With Systemic Lupus Erythematosus

    Stephanie Rush1, Laura Trupin2, Jinoos Yazdany2 and Patricia P. Katz2, 1University of California, San Francisco, San Francisco, CA, 2Medicine, University of California, San Francisco, San Francisco, CA

    The Brief Index of Lupus Damage as a Predictor of Mortality in a Cohort of Patients with Systemic Lupus Erythematosus Background/Purpose: To examine whether a…
  • Abstract Number: 607 • 2013 ACR/ARHP Annual Meeting

    Venous Thromboembolic Disease Is Associated With Increased Length Of Stay and In-Hospital Mortality In Hospitalized SLE Patients: A Multi-State, Population-Based Study

    Matthew Cascino1, Laura Trupin1, Sara Murray1, Mary Margaretten2, Edward H. Yelin3 and Jinoos Yazdany1, 1Medicine, University of California, San Francisco, San Francisco, CA, 2Rheumatology, University of California, San Francisco, San Francisco, CA, 3Arthritis Research Group, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Individuals with systemic lupus erythematosus (SLE) are at increased risk for venous thromboembolism (VTE). However, there is limited population-based data on outcomes associated with…
  • Abstract Number: 2701 • 2013 ACR/ARHP Annual Meeting

    Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus T Cell Signaling

    Alexandros P. Grammatikos1, Debjani Ghosh2 and Vasileios C. Kyttaris1, 1Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Department of Microbiology and Immunology, The Brody School of Medicine, East Carolina University, Greenville, NC

    Background/Purpose: Systemic Lupus Erythematosus (SLE) T cells display an aberrant response to CD3/ TCR stimulation. The CD3/TCR complex in SLE is characterized by the substitution…
  • Abstract Number: 1639 • 2013 ACR/ARHP Annual Meeting

    GWAS In Hispanic and Latin American Individuals Enriched For Amerindian Ancestry Identifies a New Locus Associated With Systemic Lupus Erythematosus

    Marta Eugenia Alarcon Riquelme1, Julie T. Ziegler2, Mary E. Comeau3, Elena Sanchez4, Bernado Pons-Estel5, Eduardo Acevedo6, Jorge Mariano Cucho6, Ignacio Garcia de la Torre7, Mario H. Cardiel8, Pedro Miranda9, Luis Cattogio10, Marco Maradiaga11, Jorge Esquivel-Valerio12, Jose F Moctezuma13, Mercedes Garcia14, Guillermo Berbotto15, Alejandra Babini16, Hugo Scherbarth17, Sergio Toloza18, Judith A James19, Teresa Tusie-Luna20, John B Harley21, Raphael Zidovetski22, Carl Langefeldt2 and Chaim O. Jacob23, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Wake Forest School of Medicine, Winston-Salem, NC, 3Wake Forest University Health Sciences, Winston-Salem, NC, 4King's College London, London, United Kingdom, 5Hospital Provincial de Rosario, Rosario, Argentina, 6Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, 7Hospital General de Occidente, Zapopan, Mexico, 8Centro de Investigacion Clinica de Morelia, Morelia, Mexico, 9Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, 10Hospital Italiano, Buenos Aires, Argentina, 11Hospital General de Culiacán, Culiacan, Sinaloa, Mexico, 12Hospital Universitario Dr. José Eleuterio González, Universidad Autonoma de Nuevo León, Nuevo Leon, Mexico, 13Hospital General de Mexico, Mexico, Mexico, 14Hospital San Martin, La Plata, Argentina, 15Hospital Eva Peron, Granadero Baigorria, Argentina, 16Hospital Privado de Cordoba, Cordoba, Argentina, 17H.I.G.A. Oscar E. Alende, Mar del Plata, Argentina, 18Hospital San Juan Bautista, Catamarca, Argentina, 19Oklahoma Medical Research Foundation, Oklahoma City, OK, 20Instituto de Investigaciones Biomédicas de la Universidad Nacional Autónoma de México, and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 21Childrens Hospital, Cincinnati, OH, 22University of Southern California, Los Angeles, CA, 23Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA

    Background/Purpose: Systemic lupus erythematosus (SLE), a chronic autoimmune disease with a strong genetic component, exhibits a 9:1 female to male ratio and disproportionate impact on…
  • Abstract Number: 1066 • 2013 ACR/ARHP Annual Meeting

    Depression Screening In Patients With Systemic Lupus Erythematosus From The Southeastern United States: Missing Opportunities For Early Diagnosis and Treatment

    Cristina Drenkard1, Charmayne M. Dunlop-Thomas2, Gaobin Bao3 and S. Sam Lim4, 1Department of Medicine, Emory University, Atlanta, GA, 2Medicine Rheumatology, Emory University, Atlanta, GA, 3Medicine, Emory University, Atlanta, GA, 4Emory University School of Medicine, Division of Rheumatology, Atlanta, GA

    Background/Purpose: Depression can be found in 20-60% of SLE patients and has substantial impact on quality of life, disease outcomes and health care costs. Although…
  • Abstract Number: 610 • 2013 ACR/ARHP Annual Meeting

    Disease Specific Quality Of Life Domains Are Impaired In Patients With Lupus Nephritis?

    Meenakshi Jolly1, Zineb Aouhab2, Sergio Toloza3, Ana M. Bertoli4, Ivana Blazevik5, Luis M. Vila6, Ioana Moldovan7, Karina Marianne D. Torralba8, Arif Kaya9, Berna Goker10, Mehmet E. Tezcan11, Seminur Haznedaroglu12, Josiane Bourré-Tessier13, Ann E. Clarke14, D.J. Wallace15, Michael H. Weisman16 and Graciela S. Alarcon17, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Medicine, John H Stroger Hospital, Chicago, IL, 3Hospital San Juan Bautista, Catamarca, Argentina, 4Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, 5University of Buenos Aires, Buenos Aries, Argentina, 6Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, 7Loma Linda Univ Medical Center, Loma Linda, CA, 8Rheumatology/Int Med, USC Keck Schl of Medicine, Los Angeles, CA, 9Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, 10Internal Medicine-Rheumatology, Gazi University, Ankara, Turkey, 11Rheumatology, Dr. Lutfi Kirdar Kartal EA Hastanesi, Istanbul, Turkey, 12Internal Medicine-Rheumatology, Gazi University School of Medicine, Ankara, Turkey, 13Rheumatology, McGill University, Montréal, QC, Canada, 14Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, 15Cedars-Sinai Medical Center, Los Angeles, CA, 16Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 17Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Often systemic Lupus Erythematosus (SLE) patients with Lupus Nephritis (LN) require frequent visits with their health care providers, follow up, and exposure to immunosuppressive…
  • Abstract Number: 2703 • 2013 ACR/ARHP Annual Meeting

    An Intronic CR2 Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression

    Jian Zhao1, Brendan M. Giles2, Rhonda L. Taylor3, Gabriel A. Yette2, Kara M. Lough2, Lawrence J. Abraham3, Hui Wu4, Patrick M. Gaffney5, Jennifer A. Kelly6, Kenneth M. Kaufman7,8, John B. Harley9,10, Carl D. Langefeld11, Elizabeth E. Brown12, Jeffrey C. Edberg13, Robert P. Kimberly14, Daniela Ulgiati3, Betty P. Tsao1 and Susan A. Boackle15, 1Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2University of Colorado School of Medicine, Aurora, CO, 3University of Western Australia, Perth, Western Australia, Australia, 4Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7U.S. Department of Veterans Affairs Medical Center, Cincinnati, OH, 81Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, 9Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 10US Department of Veterans Affairs Medical Center, Cincinnati, OH, 11Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 12University of Alabama at Birmingham, Birmingham, AL, 13Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 14Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 15Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by the production of antibodies to nuclear antigens, which form immune complexes that deposit in tissues and cause…
  • Abstract Number: 1607 • 2013 ACR/ARHP Annual Meeting

    Two Year Follow-Up On Biologics Use In 13 Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus

    Ronald F. van Vollenhoven1, Melinda Mild2, Søren Jacobsen3, S. Bernatsky4, Daniel J. Wallace5, Sang-Cheol Bae6, Manuel Ramos-Casals7, Francisco J. García-Hernández8, R. Ramsey-Goldman9, Andrea Doria10, Marta Mosca11, Michelle A. Petri12, M Ayala-Gutiérrez13, J.G. Hanley14 and for The SLICC group15, 1Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, 2Department of medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 4Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 7Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, 8Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain, 9Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 10Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, 11Rheumatology Unit, University of Pisa, Pisa, Italy, 12Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 13Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Carlos Haya, Malaga, Spain, 14Division of Rheumatology, Halifax, NS, Canada, 15Department of Medicine, the Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Only one biologic agent has been approved for use in SLE, but some are used off-label in various settings. To obtain systematic information regarding…
  • Abstract Number: 1070 • 2013 ACR/ARHP Annual Meeting

    Characteristics and Medication Use Patterns Among Belimumab Users In a Commercially Insured Population With Systemic Lupus Erythematosus

    Xuehua Ke1, Jeetvan Patel2, Hong Kan2, Debra F Eisenberg1 and Alan Oglesby2, 1HealthCore Inc, Wilmington, DE, 2GlaxoSmithKline, Research Triangle Park, NC

    Background/Purpose: Belimumab is a B lymphocyte stimulator-specific inhibitor approved for treatment of systemic lupus erythematosus (SLE). The purpose of the study was to describe medication…
  • Abstract Number: 562 • 2013 ACR/ARHP Annual Meeting

    The Knock-Out Of TWEAK Receptor/Fn14 Ameliorates Lupus Nephritis In MRL/Lpr Mice

    Yumin Xia1, Leal Herlitz2, Simona Gindea1, Jing Wen1, Rahul Pawar1, Alexander Misharin3, Harris R. Perlman4, Ping Wu5, Jennifer Michaelson5, Linda Burkly5 and Chaim Putterman6, 1Albert Einstein College of Medicine, Bronx, NY, 2The Department of Pathology, Columbia University Medical Center, New York, NY, 3Medicine, Division of Rheumatology, Northwestern University, Chicago, IL, 4Northwestern University, Chicago, IL, 5Biogen Idec, Cambridge, MA, 6The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Renal mesangial cells, podocytes, and tubular cells express Fn14, the sole confirmed receptor for the tumor necrosis factor (TNF)-family member cytokine TWEAK (TNF-like weak…
  • Abstract Number: 2674 • 2013 ACR/ARHP Annual Meeting

    Vitamin D Deficiency Is Common and Associated With Increased C-Reactive Protein In Children With Lupus: An Atherosclerosis Prevention In Pediatric Lupus Erythematosus Substudy

    Angela B. Robinson1, Vin Tangpricha2, Eric Yow3, Reut Gurion4, Grace McComsey4 and Laura E. Schanberg5, 1Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, 2Medicine, Emory University School of Medicine, Atlanta, GA, 3Biostatistics, Duke Clinical Research Institute, Durham, NC, 4Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, 5Pediatrics, Duke University Medical Center, Durham, NC

    Background/Purpose: Epidemiologic associations suggest vitamin D may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements,…
  • Abstract Number: 1611 • 2013 ACR/ARHP Annual Meeting

    Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients

    Ronald F. van Vollenhoven1, Melinda Mild2, Andrea Doria3, T. Dörner4, Gianfranco Ferraccioli5, Frederic Houssiau6, T.W.J. Huizinga7, David A. Isenberg8, László Kovács9, Guillermo Ruiz-Irastorza10, Danilo Squatrito11, Alexandre Voskuyl12, Marta Mosca13, G D Sebastiani14, Murat Inanç15, Gabriella Szücs16, Søren Jacobsen17, A. Castro18 and for The IRBIS-EMA group19, 1Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, 2Department of medicine, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, 4Charité University Medicine Berlin, Berlin, Germany, 5Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 6Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, 7Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 8Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 9Department of Rheumatology, University of Szeged, Szeged, Hungary, 10Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, 11Center for Autoimmune Diseases, Department of Internal Medicine, Careggi Hospital- Florence, Florence, Italy, 12Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 13Rheumatology Unit, University of Pisa, Pisa, Italy, 14Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, 15Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 16Department of Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, 17Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 18Hospital Universitari de Reus, Spain, Reus, Spain, 19ClinTRID, Department of Medicine, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Rituximab (Rituxan, Mabthera; RTX) has not been approved for use in SLE, but uncontrolled observations have suggested efficacy in some patients and the medication…
  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology